Compare Abbott Laboratories (ABT) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Abbott Laboratories trades at $110.82 (market cap $187.95B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $59.96. The key difference: Abbott Laboratories pays a 2.32% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | JEPQ | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $136.62 | $61.46 |
52-Week Low | $82.57 | $53.77 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
JEPQ trades at $60.055, up 0.63% with a bullish technical signal from moving averages. The ETF's covered-call strategy generates consistent monthly income, with recent dividends of $0.70, $0.64, and $0.56. News coverage highlights its role in retirement income strategies alongside tax considerations for distributions. Institutional interest remains strong with Bank of America increasing its stake by 8.9% in Q1 2026.
JEPQ offers attractive yield generation through its Nasdaq-focused options strategy, but investors face tax implications as distributions are taxed as ordinary income. The ETF's performance depends on market volatility for premium collection, creating both opportunity and risk during turbulent periods. Current technical strength supports near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
